Entrada Therapeutics (TRDA) Accumulated Depreciation & Amortization (2022 - 2025)
Entrada Therapeutics (TRDA) has 4 years of Accumulated Depreciation & Amortization data on record, last reported at $9.9 million in Q4 2025.
- For Q4 2025, Accumulated Depreciation & Amortization rose 5.41% year-over-year to $9.9 million; the TTM value through Dec 2025 reached $9.9 million, up 5.41%, while the annual FY2025 figure was $9.9 million, 5.41% up from the prior year.
- Accumulated Depreciation & Amortization reached $9.9 million in Q4 2025 per TRDA's latest filing, down from $11.3 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $11.3 million in Q2 2025 and bottomed at $2.3 million in Q2 2022.
- Average Accumulated Depreciation & Amortization over 4 years is $6.5 million, with a median of $5.9 million recorded in 2023.
- Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 91.53% in 2023, then rose 5.41% in 2025.
- A 4-year view of Accumulated Depreciation & Amortization shows it stood at $3.3 million in 2022, then skyrocketed by 79.43% to $5.9 million in 2023, then soared by 59.11% to $9.4 million in 2024, then grew by 5.41% to $9.9 million in 2025.
- Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $9.9 million in Q4 2025, $11.3 million in Q2 2025, and $10.3 million in Q1 2025.